argenx SEARGX

Is ARGX cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$1,007.07-26.08 (-2.52%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$65B
Large-cap
+14100%
2017 — today
10-Year Price
+4372%
2017 — today
52-Week Range
$663.93$1,058.90
Current $1,007.07· 87%

Amsterdam-based argenx SE develops innovative immunology therapies. Its lead product, efgartigimod (VYVGART, VYVGART HYTRULO, VYVDURA), addresses conditions including generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The pipeline features candidates like empasiprubart, ARGX-119, and various FcRn-targeting assets. argenx maintains global operations and strategic partnerships with firms including Genmab, AbbVie, Zai Lab, and LEO Pharma to advance its antibody portfolio.

Similar companies

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
28.6
Historically pricey
Historically pricey — last 10 years
Sector median 25.0above sector
P/B ratio
7.7
Historically pricey
Historically pricey — last 10 years
Sector median 2.6above sector
EV / EBITDA
25.9
Historically cheap
Historically cheap relative to the last 10 years
Sector median 15.5above sector
Free · No credit card needed

Get alerted when ARGX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.